Vericel (NASDAQ:VCEL) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

VCEL has been the topic of several other research reports. Piper Jaffray Companies reaffirmed a “buy” rating and set a $7.00 price objective on shares of Vericel in a research note on Thursday, August 10th. BTIG Research reaffirmed a “buy” rating and set a $6.00 price objective on shares of Vericel in a research note on Thursday, September 7th.

Shares of Vericel (VCEL) traded up $0.05 during trading on Friday, reaching $4.50. The company had a trading volume of 633,705 shares, compared to its average volume of 500,141. Vericel has a twelve month low of $2.25 and a twelve month high of $6.30. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.22 and a current ratio of 2.50.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The business had revenue of $14.26 million for the quarter. Vericel had a negative return on equity of 265.45% and a negative net margin of 45.11%. analysts expect that Vericel will post -0.6 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in VCEL. Archon Capital Management LLC bought a new position in Vericel during the 2nd quarter worth about $4,412,000. First Washington CORP bought a new position in Vericel during the 2nd quarter worth about $2,230,000. Perkins Capital Management Inc. increased its holdings in Vericel by 118.4% during the 3rd quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock worth $3,376,000 after purchasing an additional 305,000 shares in the last quarter. EAM Investors LLC bought a new position in Vericel during the 3rd quarter worth about $943,000. Finally, Vanguard Group Inc. increased its holdings in Vericel by 7.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock worth $4,002,000 after purchasing an additional 88,645 shares in the last quarter. Hedge funds and other institutional investors own 33.17% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Vericel (VCEL) Downgraded to “Sell” at ValuEngine” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/01/vericel-vcel-downgraded-to-sell-at-valuengine.html.

About Vericel

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Receive News & Stock Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related stocks with our FREE daily email newsletter.